Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Savient Pharmaceuticals Inc    SVNT

SAVIENT PHARMACEUTICALS INC (SVNT)
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Savient to Reduce Work Force in Restructuring

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 06:35pm CEST

Savient Pharmaceuticals Inc. (>> Savient Pharmaceuticals, Inc.) unveiled plans to reduce the size of its work force by more than a third as it aims to reduce its operating costs, and the specialty biopharmaceutical company also named the head of its North American commercial business as its new president and chief executive.

Shares were up 4.2% at 64 cents in recent trading. The stock has fallen about 71% this year.

The company selected Louis Ferrari, who joined Savient in February 2011, to succeed John H. Johnson, who left the company earlier this year to become chief executive at Dendreon Corp. (>> Dendreon Corporation). He takes the reigns from David Norton, who has headed Savient on an interim basis since Mr. Johnson's departure.

Savient Chairman Stephen Jaeger said that since joining Savient, Mr. Ferrari has played a key role in the continuing rollout of Krystexxa treatment for gout and development of the company's growth strategies.

The work-force reduction, which includes current vacancies, will include a restructuring of its field force to 35 key account managers and three regional business directors. Savient aims to generate annual operating cost savings of about $56 million by 2013, including roughly $6.5 million of operating expense savings in 2012.

About $4.7 million in restructuring and employee severance charges are anticipated, including $3.6 million during 2012.

Prior to joining Savient, Mr. Ferrari had a long career of increasing responsibility at health-care giant Johnson and Johnson (>> Johnson & Johnson), where he most recently served as vice president of oncology and nephrology.

Write to Tess Stynes at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.45% 126.76 Delayed Quote.-9.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAVIENT PHARMACEUTICALS IN
2013SAVIENT PHARMACEUTICALS INC : Savient Receives Approval From Bankruptcy Court To..
PU
2013SAVIENT PHARMACEUTICALS INC : Savient Reaches Agreement On Use Of Cash Collatera..
PR
2013D. E. SHAW & CO. LP 3Q 13F : Largest Eliminations -2-
DJ
2013D. E. SHAW & CO. LP 3Q 13F : Largest Eliminations
DJ
2013SAVIENT PHARMACEUTICALS INC : Savient Receives Court Approval Of Key "First Day"..
PR
2013SAVIENT PHARMACEUTICALS INC : SVNT, CZR, MTSL and FUEL added to NASDAQ Active St..
AC
2013U.S. HOT STOCKS FUTURES : Hot Stocks to Watch
DJ
2013SAVIENT PHARMACEUTICALS INC : Savient Pharmaceuticals files for Chapter 11 bankr..
RE
2013SAVIENT PHARMACEUTICALS INC : Savient Pharmaceuticals Commences Voluntary Chapte..
PR
2013SAVIENT PHARMACEUTICALS INC : Savient Announces Multiple Abstracts Related to KR..
PU
More news
Chart SAVIENT PHARMACEUTICALS IN
Duration : Period :
Savient Pharmaceuticals In Technical Analysis Chart | SVNT | US80517Q1004 | 4-Traders
Income Statement Evolution
Sector and Competitors
1st jan.Capitalization (M$)
SAVIENT PHARMACEUTICALS INC0
CELLTRION, INC.--.--%29 110
IQVIA HOLDINGS INC-1.44%20 148
LONZA GROUP-7.22%18 502
NEKTAR THERAPEUTICS38.30%13 600
INCYTE CORPORATION-34.17%13 206